Parkinson's disease (PD) is one of the most common neurodegenerative disorders with a
global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both …

Parkinson's disease (PD), as the second most common neurodegenerative disease, is
caused by complex pathological processes and currently remains very difficult to treat. PD …

Background There are currently no disease-modifying therapeutics for Parkinson's disease
(PD). Although extensive efforts were undertaken to develop therapeutic approaches to …

Neurodegenerative diseases such as Parkinson's disease (PD) are manifested by inclusion
bodies of alpha-synuclein (α-syn) also called α-synucleinopathies. Detection of these …

Aggregation of amyloidogenic proteins is a characteristic of multiple neurodegenerative
diseases. Atomic resolution of small molecule binding to such pathological protein …

This article summarizes (1) the recent achievements to further improve symptomatic therapy
of motor Parkinson's disease (PD) symptoms,(2) the still-few attempts to systematically …

The accumulation of amyloid fibrils is characteristic of neurodegenerative diseases such as
Alzheimer's disease (AD) and Parkinson's disease. Detecting these fibrils with fluorescent or …

The remarkable prevalence of pyrazole scaffolds in a versatile array of bioactive molecules
ranging from apixaban, an anticoagulant used to treat and prevent blood clots and stroke, to …

Despite decades of research, accurate diagnosis of Parkinson's disease remains a
challenge, and disease-modifying treatments are still lacking. Research into the early …

Abstract Parkinson's disease (PD), the second most common neurodegenerative movement
disorder, is characterized by progressive motor and non-motor symptoms [1]. Despite …